Developer docs
API playgroundTry for free, no card

Search company profiles

Oncidium Foundation

Full company profile

uuid000tfhn

Namestring
Oncidium Foundation
Legal namestring
Oncidium foundation
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Oncidium Foundation is a Belgium-registered nonprofit (company number 0838.388.420, headquartered in Brussels) founded in 2020 with the mission of driving equal global access to radioligand therapy (RLT) for cancer care. The organisation operates across four pillars — Access, Awareness, Advocacy, and Research/Supporting Collaborations — and structures its work around a treatment-donation channel rather than a research or commercial pipeline.

Its flagship initiative is RLT-Connect, a treatment-donation platform that connects cancer patients in financial need with radiopharmaceutical therapies by drawing on a multi-manufacturer supply chain (medical radioisotopes such as Lu-177, and ready-to-use radiopharmaceuticals including 177-Lu-PSMA). Supporting products include an interactive global therapy-center map covering 950+ sites, a 70-country ambassador network of patient advocates, the Mr. Bind educational comic/video series, the Radiotheranostics Today newsletter, and a patient-information portal spanning 11 cancer types (prostate, neuroendocrine tumours, thyroid, breast, kidney, skin, hepatocarcinoma, colorectal, pancreatic, and leukemia). Distribution is web-native and content-led (WordPress CMS, social channels on LinkedIn, Instagram, X, Facebook, YouTube) plus in-country ambassador activity and partnership-driven advocacy at institutions including the European Parliament and the IAEA.

The business model is charitable: revenue comprises individual donations, institutional grants, and corporate sponsorships from radiopharmaceutical manufacturers (Curium, Isotopia, ITM, Telix, PanTera, Shine Medical Technologies, Marken) and logistics partners. Services are free to end beneficiaries. Customer segments are cancer patients (primary), healthcare professionals (oncologists, nuclear-medicine specialists), and partner organisations (radiopharmaceutical companies, patient organisations, healthcare institutions). The foundation is governed by a board operating under conflict-of-interest procedures compliant with the Belgian Code of Companies and Associations.

Short descriptiontext

Oncidium Foundation is a Belgium-based nonprofit founded in 2020 that drives equal global access to radioligand therapy for cancer care through its RLT-Connect treatment-donation platform, a 70-country ambassador network, and 950+ partner therapy centres.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBrussels, Belgium
HQ citystring
Brussels
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radioligand therapy access, cancer treatment donation, radiotheranostics education, patient advocacy services, therapy center locator
Industry3 codes
PRIMARYHLAIAGAI
Nuclear Medicine Clinical Services & Therapy Centers
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Voluntary Health Organizations813212
SIC code2 codes
  • Services-Health Services8000
  • Services-Misc Health & Allied Services, Nec8090
Product category
Nonprofit Cancer Treatment Access / Radioligand Therapy Advocacy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Donations and Charitable Contributions
TypeGrants Donations
Description

As a foundation, Oncidium generates revenue through donations from individuals, corporations, and institutional donors to fund treatment access programs, education initiatives, and advocacy work.

oncidiumfoundation.org
2Corporate Sponsorships
TypeGrants Donations
Description

Partnerships with radiopharmaceutical companies (Curium, Isotopia, ITM, Telix, PanTera, and others) who sponsor the foundation's mission to expand access to radioligand therapy worldwide.

oncidiumfoundation.org
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Others, Technology or R&D
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 2 records shown
1RLT-Connect
Description

Treatment donation program facilitating access to radioligand therapy for patients in financial need worldwide.

oncidiumfoundation.org
+1 more record
Core offering1 text field

Oncidium Foundation is a nonprofit foundation that drives equal access to radioligand therapy (RLT) for cancer patients worldwide. Its flagship offering is RLT-Connect, a treatment donation platform that channels donated medical radioisotopes and radiopharmaceuticals (e.g., Lu-177, 177-Lu-PSMA) to cancer patients in financial need, one patient at a time. Complementary offerings include a global therapy center locator map (950+ centers), a 70-country ambassador network, and patient education resources (Mr. Bind comic series, Radiotheranostics Today newsletter, multi-cancer-type patient guides).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 74+ lives impacted through RLT-Connect treatment donation program
+2 more records
Product overview1 text field

Oncidium Foundation operates as a healthcare access organization offering a portfolio of interconnected programs and platforms centered around radioligand therapy (RLT) for cancer treatment. The core offering is RLT-Connect, a treatment donation platform that connects patients in financial need with radiopharmaceutical therapies. Supporting this are an interactive global therapy center map (950+ centers), an ambassador network spanning 70 countries, educational resources including the Mr. Bind comic book series and Radiotheranostics Today newsletters, and a comprehensive patient support platform covering information on multiple cancer types. The organization functions as a foundation facilitating access, awareness, and advocacy rather than a traditional technology product company.

Product and service5 records
1RLT-Connect Treatment Donation Program
CategoryTreatment donation program
Description

A treatment donation platform that builds access to radioligand therapy for cancer patients in financial need, channeling donated medical radioisotopes (e.g., Lu-177) and radiopharmaceuticals (e.g., 177-Lu-PSMA) one patient at a time through partner hospitals and corporate sponsors such as Curium, Isotopia, ITM, PanTera, Shine Medical, and Marken.

2Interactive Global Therapy Center Locator Map
CategoryPatient access service
Description

An interactive worldwide map listing 950+ radioligand therapy centers, enabling patients and clinicians to identify the nearest qualified treatment location.

3Mr. Bind Educational Comic Book and Video Series
CategoryPatient and public education
Description

An educational comic book and video series featuring the character Mister Bind that explains radiotheranostics concepts in plain language for patients, caregivers, and the general public.

4Patient Support Platform
CategoryPatient education and navigation
Description

An online platform providing information and guidance for cancer patients across 11 cancer types (prostate, NETs, thyroid, breast, kidney, skin, hepatocarcinoma, colorectal, pancreatic, leukemia, plus others), including clinical trial information and patient stories.

5Radiotheranostics Resources Portal and Radiotheranostics Today Newsletter
CategoryProfessional and patient education
Description

An online resources portal and recurring newsletter (Radiotheranostics Today) providing educational materials about radiotheranostics for healthcare professionals and patients.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-11
Description

Partnership signed during Belgian Economic Mission to Turkiye to strengthen supply chain of RLT-Connect program. Curium provides medical radioisotopes (Lu-177) and ready-to-use radiopharmaceuticals (177-Lu-PSMA) as main supplier. Curium is a global radiopharmaceutical leader bringing manufacturing and distribution expertise.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Corporate sponsor and RLT-Connect partner providing medical radioisotope products for treatment donation program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Corporate sponsor and RLT-Connect partner, supplying medical radioisotopes for radioligand therapy access programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Corporate sponsor supporting foundation's mission to expand access to radioligand therapy worldwide.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Corporate sponsor and RLT-Connect partner contributing to radiopharmaceutical supply chain.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

RLT-Connect partner providing medical radioisotope production for treatment donation program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Corporate sponsor and RLT-Connect partner specializing in logistics for radiopharmaceutical distribution.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Institutions & Programs partner collaborating on nuclear medicine and radiopharmaceutical therapy access initiatives.

9ALASBIMN
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Institutions & Programs partner in Latin American nuclear medicine community supporting radiotheranostics access.

oncidiumfoundation.org
10Accelerate EU Project
Strategic tierCoreTypeStrategic or Co-development Partner
Description

European project partner working on accelerating access to radioligand therapy in Europe.

oncidiumfoundation.org
11Thera
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Institutions & Programs partner contributing to nuclear medicine therapy access initiatives.

oncidiumfoundation.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Brazilian National Cancer Institute as Institutions & Programs partner supporting radioligand therapy access in Brazil.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Brazilian healthcare institution as Institutions & Programs partner providing cancer treatment access.

14Fundación ACIAPO
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Patient organization partner in Argentina working with Oncidium on advocacy for insurance coverage expansion.

oncidiumfoundation.org
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

European partner that invited Oncidium Foundation CEO to European Parliament panel on RLT policy and reality.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1American Cancer Society
TypeBroad incumbent
Description

The largest US cancer-focused nonprofit, providing patient support, advocacy, and access programs comparable in mission to Oncidium's cancer access and education work, though operating at much broader scale across all cancer types rather than RLT-specific.

TypeBroad incumbent
Description

Large global health access organization negotiating pricing and supply agreements for therapies in LMICs—analogous function to Oncidium's radiopharma negotiation role but at pharmaceutical-level scale and scope.

3International Myeloma Foundation
TypeEmerging player
Description

Dedicated cancer-type foundation providing patient education, access support, and advocacy—comparable in mission and operating model to Oncidium but focused on a single disease rather than a single therapy modality.

TypeDirect peer
Description

A nonprofit focused on expanding access to medical treatments for underserved populations globally, analogous to RLT-Connect's donation model connecting patients to therapies they could not otherwise afford.

TypeDirect peer
Description

The IAEA's flagship program to expand access to nuclear medicine and radiopharmaceutical therapies in low- and middle-income countries—directly aligned with and a partner of Oncidium, and a potential future channel-participant in the same access space.

TypeEmerging player
Description

Cancer-specific nonprofit combining research funding, patient education, and advocacy—parallel to Oncidium's Access/Awareness/Advocacy pillars at smaller disease-specific scale.

TypeDirect peer
Description

Global health nonprofit operating in 100+ countries providing medicines, supplies, and health system support—comparable international scale and donation-supported healthcare access model to Oncidium.

TypeDirect peer
Description

US nonprofit providing case management and access support to patients facing serious illness, including navigating insurance and reimbursement—directly parallel to RLT-Connect's patient navigation function.

TypeEmerging player
Description

Cancer-focused nonprofit funding immunotherapy research and patient education—comparable foundation operating model but with research orientation rather than Oncidium's treatment access focus.

TypeDirect peer
Description

Umbrella pan-European patient advocacy organization that represents cancer patients in EU policy discussions including reimbursement and access—closely aligned with Oncidium's European Parliament advocacy work.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncidium Foundation

Nonprofit Cancer Treatment Access / Radioligand Therapy Advocacyoncidiumfoundation.org

Oncidium Foundation is a Belgium-based nonprofit founded in 2020 that drives equal global access to radioligand therapy for cancer care through its RLT-Connect treatment-donation platform, a 70-country ambassador network, and 950+ partner therapy centres.

What Oncidium Foundation does

Oncidium Foundation is a Belgium-registered nonprofit (company number 0838.388.420, headquartered in Brussels) founded in 2020 with the mission of driving equal global access to radioligand therapy (RLT) for cancer care. The organisation operates across four pillars — Access, Awareness, Advocacy, and Research/Supporting Collaborations — and structures its work around a treatment-donation channel rather than a research or commercial pipeline.

Its flagship initiative is RLT-Connect, a treatment-donation platform that connects cancer patients in financial need with radiopharmaceutical therapies by drawing on a multi-manufacturer supply chain (medical radioisotopes such as Lu-177, and ready-to-use radiopharmaceuticals including 177-Lu-PSMA). Supporting products include an interactive global therapy-center map covering 950+ sites, a 70-country ambassador network of patient advocates, the Mr. Bind educational comic/video series, the Radiotheranostics Today newsletter, and a patient-information portal spanning 11 cancer types (prostate, neuroendocrine tumours, thyroid, breast, kidney, skin, hepatocarcinoma, colorectal, pancreatic, and leukemia). Distribution is web-native and content-led (WordPress CMS, social channels on LinkedIn, Instagram, X, Facebook, YouTube) plus in-country ambassador activity and partnership-driven advocacy at institutions including the European Parliament and the IAEA.

The business model is charitable: revenue comprises individual donations, institutional grants, and corporate sponsorships from radiopharmaceutical manufacturers (Curium, Isotopia, ITM, Telix, PanTera, Shine Medical Technologies, Marken) and logistics partners. Services are free to end beneficiaries. Customer segments are cancer patients (primary), healthcare professionals (oncologists, nuclear-medicine specialists), and partner organisations (radiopharmaceutical companies, patient organisations, healthcare institutions). The foundation is governed by a board operating under conflict-of-interest procedures compliant with the Belgian Code of Companies and Associations.

Oncidium Foundation firmographics

Firmographics
Name
Oncidium Foundation
Legal name
Oncidium foundation
Website
https://oncidiumfoundation.org
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Oncidium Foundation is a Belgium-based nonprofit founded in 2020 that drives equal global access to radioligand therapy for cancer care through its RLT-Connect treatment-donation platform, a 70-country ambassador network, and 950+ partner therapy centres.
Ownership category
akta.pro rank

Oncidium Foundation industry classification

Industry
Product category
Nonprofit Cancer Treatment Access / Radioligand Therapy Advocacy
NAICS
Voluntary Health Organizations (813212)
SIC
Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAIAGAI
Nuclear Medicine Clinical Services & Therapy Centers
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Radioligand therapy access
  • Cancer treatment donation
  • Radiotheranostics education
  • Patient advocacy services
  • Therapy center locator

Where Oncidium Foundation is headquartered

Location

Headquarters

HQ city
Brussels
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Oncidium Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others, Technology or R&D

Revenue model

  1. Donations and Charitable Contributions: As a foundation, Oncidium generates revenue through donations from individuals, corporations, and institutional donors to fund treatment access programs, education initiatives, and advocacy work.
  2. Corporate Sponsorships: Partnerships with radiopharmaceutical companies (Curium, Isotopia, ITM, Telix, PanTera, and others) who sponsor the foundation's mission to expand access to radioligand therapy worldwide.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Oncidium Foundation product offering

Product offering

Core offering

Oncidium Foundation is a nonprofit foundation that drives equal access to radioligand therapy (RLT) for cancer patients worldwide. Its flagship offering is RLT-Connect, a treatment donation platform that channels donated medical radioisotopes and radiopharmaceuticals (e.g., Lu-177, 177-Lu-PSMA) to cancer patients in financial need, one patient at a time. Complementary offerings include a global therapy center locator map (950+ centers), a 70-country ambassador network, and patient education resources (Mr. Bind comic series, Radiotheranostics Today newsletter, multi-cancer-type patient guides).

Product overview

Oncidium Foundation operates as a healthcare access organization offering a portfolio of interconnected programs and platforms centered around radioligand therapy (RLT) for cancer treatment. The core offering is RLT-Connect, a treatment donation platform that connects patients in financial need with radiopharmaceutical therapies. Supporting this are an interactive global therapy center map (950+ centers), an ambassador network spanning 70 countries, educational resources including the Mr. Bind comic book series and Radiotheranostics Today newsletters, and a comprehensive patient support platform covering information on multiple cancer types. The organization functions as a foundation facilitating access, awareness, and advocacy rather than a traditional technology product company.

Differentiator

Problem solved

Functional benefit

Brands

  • RLT-Connect: Treatment donation program facilitating access to radioligand therapy for patients in financial need worldwide.
  • Radiotheranostics Today

Products and services

  • RLT-Connect Treatment Donation Program A treatment donation platform that builds access to radioligand therapy for cancer patients in financial need, channeling donated medical radioisotopes (e.g., Lu-177) and radiopharmaceuticals (e.g., 177-Lu-PSMA) one patient at a time through partner hospitals and corporate sponsors such as Curium, Isotopia, ITM, PanTera, Shine Medical, and Marken.
  • Interactive Global Therapy Center Locator Map An interactive worldwide map listing 950+ radioligand therapy centers, enabling patients and clinicians to identify the nearest qualified treatment location.
  • Mr. Bind Educational Comic Book and Video Series An educational comic book and video series featuring the character Mister Bind that explains radiotheranostics concepts in plain language for patients, caregivers, and the general public.
  • Patient Support Platform An online platform providing information and guidance for cancer patients across 11 cancer types (prostate, NETs, thyroid, breast, kidney, skin, hepatocarcinoma, colorectal, pancreatic, leukemia, plus others), including clinical trial information and patient stories.
  • Radiotheranostics Resources Portal and Radiotheranostics Today Newsletter An online resources portal and recurring newsletter (Radiotheranostics Today) providing educational materials about radiotheranostics for healthcare professionals and patients.

Quantifiable outcome

  • 74+ lives impacted through RLT-Connect treatment donation program
  • +2 more outcomes

Companies that use Oncidium Foundation

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Oncidium Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Oncidium Foundation partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and flagship.

  • CuriumcoreStrategic or Co-development Partner · 11 May 2026Partnership signed during Belgian Economic Mission to Turkiye to strengthen supply chain of RLT-Connect program. Curium provides medical radioisotopes (Lu-177) and ready-to-use radiopharmaceuticals (177-Lu-PSMA) as main supplier. Curium is a global radiopharmaceutical leader bringing manufacturing and distribution expertise.
  • IsotopiacoreStrategic or Co-development PartnerCorporate sponsor and RLT-Connect partner providing medical radioisotope products for treatment donation program.
  • ITM Isotope Technologies MunichcoreStrategic or Co-development PartnerCorporate sponsor and RLT-Connect partner, supplying medical radioisotopes for radioligand therapy access programs.
  • Telix PharmaceuticalscoreStrategic or Co-development PartnerCorporate sponsor supporting foundation's mission to expand access to radioligand therapy worldwide.
  • PanTeracoreStrategic or Co-development PartnerCorporate sponsor and RLT-Connect partner contributing to radiopharmaceutical supply chain.
  • Shine Medical TechnologiescoreStrategic or Co-development PartnerRLT-Connect partner providing medical radioisotope production for treatment donation program.
  • MarkencoreStrategic or Co-development PartnerCorporate sponsor and RLT-Connect partner specializing in logistics for radiopharmaceutical distribution.
  • International Atomic Energy Agency (IAEA)flagshipStrategic or Co-development PartnerInstitutions & Programs partner collaborating on nuclear medicine and radiopharmaceutical therapy access initiatives.
  • ALASBIMNcoreStrategic or Co-development PartnerInstitutions & Programs partner in Latin American nuclear medicine community supporting radiotheranostics access.
  • Accelerate EU ProjectcoreStrategic or Co-development PartnerEuropean project partner working on accelerating access to radioligand therapy in Europe.
  • TheracoreStrategic or Co-development PartnerInstitutions & Programs partner contributing to nuclear medicine therapy access initiatives.
  • INCA (Instituto Nacional de Cancer)coreStrategic or Co-development PartnerBrazilian National Cancer Institute as Institutions & Programs partner supporting radioligand therapy access in Brazil.
  • Hospital de AmorcoreStrategic or Co-development PartnerBrazilian healthcare institution as Institutions & Programs partner providing cancer treatment access.
  • Fundación ACIAPOcoreStrategic or Co-development PartnerPatient organization partner in Argentina working with Oncidium on advocacy for insurance coverage expansion.
  • SPARC EuropeflagshipStrategic or Co-development PartnerEuropean partner that invited Oncidium Foundation CEO to European Parliament panel on RLT policy and reality.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Oncidium Foundation competitors and assessment

Company assessment

Broad incumbents

  • American Cancer Society: The largest US cancer-focused nonprofit, providing patient support, advocacy, and access programs comparable in mission to Oncidium's cancer access and education work, though operating at much broader scale across all cancer types rather than RLT-specific.
  • Clinton Health Access Initiative (CHAI): Large global health access organization negotiating pricing and supply agreements for therapies in LMICs—analogous function to Oncidium's radiopharma negotiation role but at pharmaceutical-level scale and scope.

Emerging players

  • International Myeloma Foundation: Dedicated cancer-type foundation providing patient education, access support, and advocacy—comparable in mission and operating model to Oncidium but focused on a single disease rather than a single therapy modality.
  • LUNGevity Foundation: Cancer-specific nonprofit combining research funding, patient education, and advocacy—parallel to Oncidium's Access/Awareness/Advocacy pillars at smaller disease-specific scale.
  • Cancer Research Institute: Cancer-focused nonprofit funding immunotherapy research and patient education—comparable foundation operating model but with research orientation rather than Oncidium's treatment access focus.

Direct peers

  • Direct Relief: A nonprofit focused on expanding access to medical treatments for underserved populations globally, analogous to RLT-Connect's donation model connecting patients to therapies they could not otherwise afford.
  • IAEA Rays of Hope Initiative: The IAEA's flagship program to expand access to nuclear medicine and radiopharmaceutical therapies in low- and middle-income countries—directly aligned with and a partner of Oncidium, and a potential future channel-participant in the same access space.
  • Project HOPE: Global health nonprofit operating in 100+ countries providing medicines, supplies, and health system support—comparable international scale and donation-supported healthcare access model to Oncidium.
  • National Patient Advocate Foundation: US nonprofit providing case management and access support to patients facing serious illness, including navigating insurance and reimbursement—directly parallel to RLT-Connect's patient navigation function.
  • European Cancer Patient Coalition: Umbrella pan-European patient advocacy organization that represents cancer patients in EU policy discussions including reimbursement and access—closely aligned with Oncidium's European Parliament advocacy work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Oncidium Foundation social profiles

Digital presence

Oncidium Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncidium Foundation leadership team

Management profile

Number of profiles

Profiles3 records

Oncidium Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncidium Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncidium Foundation

What does Oncidium Foundation do?

Oncidium Foundation is a nonprofit foundation that drives equal access to radioligand therapy (RLT) for cancer patients worldwide. Its flagship offering is RLT-Connect, a treatment donation platform that channels donated medical radioisotopes and radiopharmaceuticals (e.g., Lu-177, 177-Lu-PSMA) to cancer patients in financial need, one patient at a time. Complementary offerings include a global therapy center locator map (950+ centers), a 70-country ambassador network, and patient education resources (Mr. Bind comic series, Radiotheranostics Today newsletter, multi-cancer-type patient guides).

Is Oncidium Foundation a public or private company?

Oncidium Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Oncidium Foundation founded?

Oncidium Foundation was founded in 2020. It employs 51 to 100 people.

Where is Oncidium Foundation based?

Oncidium Foundation is headquartered in Brussels, Belgium, in the Europe region.

How does Oncidium Foundation make money?

Two revenue lines are on record. Donations and Charitable Contributions are the primary driver. The others are corporate Sponsorships.

Who are Oncidium Foundation's main competitors?

Broad incumbents on record are American Cancer Society and Clinton Health Access Initiative (CHAI). Emerging players are International Myeloma Foundation, LUNGevity Foundation and Cancer Research Institute. Direct peers are Direct Relief, IAEA Rays of Hope Initiative, Project HOPE, National Patient Advocate Foundation and European Cancer Patient Coalition.

Does Oncidium Foundation have an API?

No public API is recorded for Oncidium Foundation.

What industry is Oncidium Foundation in?

Oncidium Foundation's product category is Nonprofit Cancer Treatment Access / Radioligand Therapy Advocacy. Its primary akta.pro industry code is HLAIAGAI, Nuclear Medicine Clinical Services & Therapy Centers, with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 813212 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals